Glenmark partners with Pfizer to launch atopic dermatitis drug Abrocitinib in India

Glenmark and Pfizer will co‐market abrocitinib in India under the brand names JABRYUS and CIBINQO

Pfizer and Glenmark Pharmaceuticals have joined hands to launch abrocitinib, a first-of-its-kind oral advanced systemic treatment for moderate‐to‐severe atopic dermatitis (AD), in India. Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.

When launched in India, it will be co‐marketed under the brand names JABRYUS and CIBINQO by Glenmark and Pfizer respectively. This collaboration combines the expertise of the companies to offer a groundbreaking treatment for moderate‐to‐severe AD, with improved efficacy and oral convenience to patients. Abrocitinib (CIBINQO) is available in over 35 markets globally, including the US, Japan, and China.

Meenakshi Nevatia, Country President and MD, Pfizer India, “We believe in abrocitinib’s transformative potential. Its approval is a milestone in bringing high‐quality treatment for moderate‐to‐severe atopic dermatitis in India, enabling patients to manage symptoms more effectively. Our collaboration with Glenmark will help leverage the collective strengths and capabilities of our organisations to

make this breakthrough therapy available to patients and physicians across our country.”

Alok Malik, President and Business Head ‐ India Formulations, Glenmark Pharmaceuticals said, “We are excited to collaborate with Pfizer India for the launch of abrocitinib in the country. The prevalence of atopic

dermatitis in India has been reported to be increasing owing to changes in environmental factors with symptoms appearing during the initial years of life in around 80 per cent of patients. This partnership will help us ensure the availability of this effective treatment for the Indian

patients suffering from moderate‐to‐severe AD; and further strengthen our position in the dermatology therapy space.”